briakinumab
Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. — Wikipedia
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2000 (NCT00007163)
Timeline
Indications
Mechanism of action
- Interleukin-12 subunit betaINHIBITOR
IL12B inhibitor
IgG1 monoclonal antibody with genetically engineered complementarity-determining regions that have high affinity for the IL-12/23 p40 subunit protein.
- Interleukin-23INHIBITOR
Interleukin-23 inhibitor
IgG1 monoclonal antibody with genetically engineered complementarity-determining regions that have high affinity for the IL-12/23 p40 subunit protein.
- Interleukin-12INHIBITOR
Interleukin-12 inhibitor
IgG1 monoclonal antibody with genetically engineered complementarity-determining regions that have high affinity for the IL-12/23 p40 subunit protein.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBriakinumab ↗
- ChEMBLCHEMBL1742995 ↗
Also known as
- a-796874.0
- abt-874
- abt-874
- briakinumab
- briakinumab
- briakinumab
- bsf-415977
- j695
- j695
- j-695
- lu-415977
- ozespa
- way-165772
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01260844 | Phase 1 | Apr 1, 2011 | Abbott |
| NCT00870948 | Phase 1 | Jan 1, 2009 | Abbott |
| NCT00710580 | Phase 3 | Jul 1, 2008 | AbbVie, Paragon Biomedical |
| NCT00691964 | Phase 3 | May 1, 2008 | AbbVie, Paragon Biomedical |
| NCT00679731 | Phase 3 | Apr 1, 2008 | AbbVie |
| NCT00626002 | Phase 3 | Feb 1, 2008 | AbbVie |
| NCT00570986 | Phase 3 | Nov 1, 2007 | AbbVie |
| NCT00562887 | Phase 2 | Nov 1, 2007 | Abbott |
| NCT00292396 | Phase 2 | Nov 1, 2005 | AbbVie |
| NCT00086671 | Phase 2 | Apr 1, 2004 | AbbVie |
| NCT00007163 | Phase 1 | Dec 1, 2000 | National Institute of Allergy and Infectious Diseases (NIAID) |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 7 | 7 | 2 | 2004 |
| Abbott | For profit | 3 | 3 | 2 | 2007 |
| Paragon Biomedical | For profit | 2 | 0 | 1 | 2008 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2000 |